Molecular Therapy: Oncolytics (Mar 2022)

A novel fusion protein scaffold 18/12/TxM activates the IL-12, IL-15, and IL-18 receptors to induce human memory-like natural killer cells

  • Celia C. Cubitt,
  • Ethan McClain,
  • Michelle Becker-Hapak,
  • Jennifer A. Foltz,
  • Pamela Wong,
  • Julia A. Wagner,
  • Carly C. Neal,
  • Nancy D. Marin,
  • Lynne Marsala,
  • Mark Foster,
  • Timothy Schappe,
  • Patrick Soon-Shiong,
  • John Lee,
  • Melissa M. Berrien-Elliott,
  • Todd A. Fehniger

Journal volume & issue
Vol. 24
pp. 585 – 596

Abstract

Read online

Natural killer (NK) cells are cytotoxic innate lymphoid cells that are emerging as a cellular immunotherapy for various malignancies. NK cells are particularly dependent on interleukin (IL)-15 for their survival, proliferation, and cytotoxic function. NK cells differentiate into memory-like cells with enhanced effector function after a brief activation with IL-12, IL-15, and IL-18. N-803 is an IL-15 superagonist composed of an IL-15 mutant (IL-15N72D) bound to the sushi domain of IL-15Rα fused to the Fc region of IgG1, which results in physiological trans-presentation of IL-15. Here, we describe the creation of a novel triple-cytokine fusion molecule, 18/12/TxM, using the N-803 scaffold fused to IL-18 via the IL-15N72D domain and linked to a heteromeric single-chain IL-12 p70 by the sushi domain of the IL-15Rα. This molecule displays trispecific cytokine activity through its binding and signaling through the individual cytokine receptors. Compared with activation with the individual cytokines, 18/12/TxM induces similar short-term activation and memory-like differentiation of NK cells on both the transcriptional and protein level and identical in vitro and in vivo anti-tumor activity. Thus, N-803 can be modified as a functional scaffold for the creation of cytokine immunotherapies with multiple receptor specificities to activate NK cells for adoptive cellular therapy.

Keywords